(VIANEWS) - Flaherty & Crumrine (FFC), BlackRock Income Trust (BKT), One Liberty Properties (OLP) are the highest dividend yield stocks on this list.
| Rank |
Financial Asset |
Price |
Change |
Forward Dividend Yield |
Updated (EST) |
| 1 |
Flaherty & Crumrine (FFC) |
22.98 |
0.02% |
6.74% |
2021-09-02 19:14:45 |
| 2 |
BlackRock Income Trust (BKT) |
6.39 |
0.12% |
6.48% |
2021-09-02 10:49:09 |
| 3 |
One Liberty Properties (OLP) |
31.95 |
-0.19% |
5.63% |
2021-09-03 08:10:06 |
| 4 |
Gilead Sciences (GILD) |
71.96 |
-0.53% |
4.1% |
2021-09-03 15:08:39 |
| 5 |
Bonanza Creek Energy (BCEI) |
41.57 |
5.51% |
3.51% |
2021-09-02 09:48:11 |
Close to 2K companies listed in the Nasdaq and NYSE pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. Flaherty & Crumrine (FFC) - Dividend Yield: 6.74%
Flaherty & Crumrine Preferred Securities Income Fund Inc. is a closed-ended balanced mutual fund launched and managed by Flaherty & Crumrine Incorporated. The fund invests in the public equity and fixed income markets of the United States. It seeks to invest in securities of companies operating across diversified sectors. The fund primarily invests in investment grade preferred securities consisting of hybrid or taxable preferreds. It employs quantitative analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the Merrill Lynch 8% Capped DRD Preferred Stock Index, Merrill Lynch Hybrid Preferred Securities Index, and Merrill Lynch Adjustable Preferred Stock 7% Constrained Index. It was formerly known as Flaherty & Crumrine/Claymore Preferred Securities Income Fund Incorporated. Flaherty & Crumrine Preferred Securities Income Fund Inc. was formed on May 23, 2002 and is domiciled in the United States.
Volume
Today's last reported volume for Flaherty & Crumrine is 37629, 57.89% below its average volume of 89362.
Flaherty & Crumrine's last close was $22.98, 3.65% under its 52-week high of $23.85.
Flaherty & Crumrine's Revenue
Year-on-year quarterly revenue growth declined by 1.1%, now sitting on 79.12M for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Flaherty & Crumrine's stock is considered to be oversold (<=20).
Flaherty & Crumrine's Stock Yearly Top and Bottom Value
Flaherty & Crumrine's stock is valued at $22.98 at 20:15 EST, under its 52-week high of $23.85 and way higher than its 52-week low of $20.30.
Flaherty & Crumrine's Moving Average
Flaherty & Crumrine's worth is below its 50-day moving average of $22.99 and above its 200-day moving average of $22.82.
More news about
Flaherty & Crumrine.
2. BlackRock Income Trust (BKT) - Dividend Yield: 6.48%
BlackRock Income Trust, Inc. is a closed ended fixed income mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the fixed income markets of the United States. The fund invests in securities of companies that operate across diversified sectors. It invests in securities such as U.S. government sponsored agency securities, non-agency mortgage-backed securities, asset-backed securities, and U.S. treasury obligations. The fund invests its assets in securities that are issued or guaranteed by the US government or one of its agencies or instrumentalities or rated at the time of investment either AAA by S&P or Aaa by Moody's. BlackRock Income Trust, Inc. was formed on July 22, 1988 and is domiciled in the United States.
Volume
Today's last reported volume for BlackRock Income Trust is 41430, 77.3% below its average volume of 182517.
BlackRock Income Trust's last close was $6.37, 2.15% under its 52-week high of $6.51.
BlackRock Income Trust's Revenue
Year-on-year quarterly revenue growth declined by 8.8%, now sitting on 23.06M for the twelve trailing months.
BlackRock Income Trust's Stock Yearly Top and Bottom Value
BlackRock Income Trust's stock is valued at $6.39 at 20:15 EST, below its 52-week high of $6.51 and above its 52-week low of $6.00.
BlackRock Income Trust's Moving Average
BlackRock Income Trust's value is above its 50-day moving average of $6.38 and above its 200-day moving average of $6.23.
More news about
BlackRock Income Trust.
3. One Liberty Properties (OLP) - Dividend Yield: 5.63%
One Liberty is a self-administered and self-managed real estate investment trust incorporated in Maryland in 1982. The Company acquires, owns and manages a geographically diversified portfolio consisting primarily of industrial, retail, restaurant, health and fitness and theater properties. Many of these properties are subject to long term net leases under which the tenant is typically responsible for the property's real estate taxes, insurance and ordinary maintenance and repairs.
Volume
Today's last reported volume for One Liberty Properties is 26752, 56.84% below its average volume of 61978.
One Liberty Properties's last close was $31.95, 0.78% under its 52-week high of $32.20.
One Liberty Properties's Sales
One Liberty Properties's sales growth is a negative 12.9% for the current quarter and a decline by 10.3% for the next.
One Liberty Properties's Revenue
Year-on-year quarterly revenue growth declined by 2.5%, now sitting on 80.76M for the twelve trailing months.
One Liberty Properties's Stock Yearly Top and Bottom Value
One Liberty Properties's stock is valued at $31.95 at 20:15 EST, under its 52-week high of $32.20 and way above its 52-week low of $14.93.
One Liberty Properties's Moving Average
One Liberty Properties's value is above its 50-day moving average of $30.62 and way above its 200-day moving average of $26.48.
More news about
One Liberty Properties.
4. Gilead Sciences (GILD) - Dividend Yield: 4.1%
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
Volume
Today's last reported volume for Gilead Sciences is 3851060, 38.65% below its average volume of 6277050.
Gilead Sciences's last close was $72.34, 1.36% under its 52-week high of $73.34.
The company's growth estimates for the current quarter is 55.9% and a drop 20.4% for the next.
Gilead Sciences's Revenue
Year-on-year quarterly revenue growth grew by 20.9%, now sitting on 26.64B for the twelve trailing months.
Gilead Sciences's Stock Yearly Top and Bottom Value
Gilead Sciences's stock is valued at $71.96 at 20:15 EST, under its 52-week high of $73.34 and way higher than its 52-week low of $56.56.
Gilead Sciences's Moving Average
Gilead Sciences's value is higher than its 50-day moving average of $70.11 and above its 200-day moving average of $67.08.
More news about
Gilead Sciences.
5. Bonanza Creek Energy (BCEI) - Dividend Yield: 3.51%
Bonanza Creek Energy, Inc., an exploration and production company, focuses on the extraction of onshore oil and related liquids-rich natural gas in the United States. Its primary oil and liquids-weighted assets are located in the Wattenberg Field in Colorado. As of December 31, 2019, the company had proved reserves of 121.9 million barrel of oil equivalent. Bonanza Creek Energy, Inc. was founded in 1999 and is headquartered in Denver, Colorado.
Volume
Today's last reported volume for Bonanza Creek Energy is 89761, 82.37% below its average volume of 509101.
Bonanza Creek Energy's last close was $38.88, 23.73% under its 52-week high of $50.98.
Bonanza Creek Energy's Sales
Bonanza Creek Energy's sales growth is 275.2% for the present quarter and 153.1% for the next. The company's growth estimates for the current quarter and the next is 118% and 218%, respectively.
Bonanza Creek Energy's Revenue
Year-on-year quarterly revenue growth grew by 331.1%, now sitting on 351.69M for the twelve trailing months.
Bonanza Creek Energy's Stock Yearly Top and Bottom Value
Bonanza Creek Energy's stock is valued at $41.57 at 20:15 EST, way below its 52-week high of $50.98 and way higher than its 52-week low of $15.88.
Bonanza Creek Energy's Moving Average
Bonanza Creek Energy's worth is way above its 50-day moving average of $37.56 and above its 200-day moving average of $38.42.
More news about
Bonanza Creek Energy.
